HSPA5 and metabolic dysfunction-associated steatotic liver disease: Thus, gut-secreted HSP70 and GRP78 are molecular targets for the treatment of T2D and NAFLD, whose inhibition shows a similarly high efficacy to that of metabolic surgery.